End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24,950 KRW | -3.85% | -1.96% | -3.48% |
2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Sales 2024 * | 120B 88.44M | Sales 2025 * | 145B 107M | Capitalization | 195B 144M |
---|---|---|---|---|---|
Net income 2024 * | 23B 16.95M | Net income 2025 * | 30B 22.11M | EV / Sales 2024 * | 0.56 x |
Net cash position 2024 * | 128B 94.63M | Net cash position 2025 * | 152B 112M | EV / Sales 2025 * | 0.29 x |
P/E ratio 2024 * |
8.92
x | P/E ratio 2025 * |
6.8
x | Employees | 142 |
Yield 2024 * |
3.01% | Yield 2025 * |
3.01% | Free-Float | 56.96% |
1 day | -3.85% | ||
1 week | -1.96% | ||
Current month | -4.04% | ||
1 month | +6.17% | ||
3 months | -7.93% | ||
6 months | +3.96% | ||
Current year | -3.48% |
Managers | Title | Age | Since |
---|---|---|---|
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 12-07-31 |
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 00-06-30 |
Woo-Jae Lim
BRD | Director/Board Member | 45 | 21-03-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 00-06-30 |
Dong-Jin Choi
BRD | Director/Board Member | 64 | 19-03-20 |
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 12-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 24,950 | -3.85% | 138,743 |
24-05-13 | 25,950 | -1.33% | 84,245 |
24-05-10 | 26,300 | +2.94% | 89,126 |
24-05-09 | 25,550 | +0.59% | 60,186 |
24-05-08 | 25,400 | -0.20% | 29,510 |
End-of-day quote Korea S.E., May 13, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.48% | 143M | |
+0.43% | 264B | |
+18.26% | 20.44B | |
+11.36% | 12.29B | |
-11.84% | 9.5B | |
+16.55% | 7.6B | |
+13.64% | 6.16B | |
-6.69% | 4.24B | |
-14.99% | 3.92B | |
-7.58% | 3.67B |
- Stock Market
- Equities
- A092730 Stock